Vestal Point Capital LP Decreases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vestal Point Capital LP decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 15.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 425,000 shares of the company’s stock after selling 75,000 shares during the quarter. Vestal Point Capital LP owned 0.60% of Nurix Therapeutics worth $9,550,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Amalgamated Bank grew its stake in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. Quest Partners LLC increased its stake in Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the last quarter. ClariVest Asset Management LLC lifted its position in shares of Nurix Therapeutics by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after buying an additional 1,766 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NRIX shares. Robert W. Baird began coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price target for the company. Stephens restated an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research note on Monday, October 14th. Oppenheimer boosted their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, November 6th. Finally, UBS Group initiated coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 target price on the stock. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christine Ring sold 5,760 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the completion of the transaction, the insider now owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. This represents a 18.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,451 shares of company stock valued at $663,160. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Stock Down 2.6 %

Shares of NRIX stock opened at $21.23 on Friday. The business’s fifty day moving average price is $24.09 and its 200 day moving average price is $21.70. Nurix Therapeutics, Inc. has a 1-year low of $5.68 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.